Reply to “Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study”-Reference-Cited by-同舟云学术

Reply to “Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study”

Published:2022-12 Issue:6 Volume:87 Page:e239-e240
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Ruggiero Angelo,Potestio Luca,Camela Elisa,Fabbrocini Gabriella,Megna Matteo

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study;Khanna;J Am Acad Dermatol,2022

2. QuantiFERON-TB Gold conversion is not uncommon in patients with psoriasis undergoing anti-tumour necrosis factor-α therapy;Megna;Br J Dermatol,2020

3. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study;Megna;Int J Dermatol,2021

4. Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat. Published online April 11, 2022:1-5. https://doi.org/10.1080/09546634.2022.2062280

5. A drug safety evaluation of risankizumab for psoriasis;Huang;Expert Opin Drug Saf,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to “Routine Re-screening for Latent Tuberculosis Has Low Utility in Patients With Chronic Immune-Mediated Inflammatory Diseases Treated With Biologics: A Single Center Retrospective Cohort Study”;Journal of the American Academy of Dermatology;2022-12